The POSITIVE trial has finally provided the long-awaited clarity for women facing the dilemma of pregnancy after hormone receptor-positive breast cancer treatment. This study, led by Dr. Ann Partridge, has shown that a carefully managed pause in endocrine therapy can be both feasible and safe, offering a glimmer of hope for young patients. The findings, presented at the 43rd Annual Miami Breast Cancer Conference, are particularly significant for nulliparous women in their late 30s, who often face the most pressing fertility concerns.
What makes this study so compelling is the fact that it challenges long-standing assumptions about the feasibility of pregnancy after breast cancer. Dr. Partridge, the principal investigator, boldly stated, "I’m going to show you some data that suggest what he said is garbage." This sentiment reflects the frustration many oncologists and patients have felt due to the lack of concrete guidance on this issue. The POSITIVE trial, however, has provided rigorous and reassuring evidence that a 2-year interruption of endocrine therapy can lead to healthy pregnancies without compromising oncologic outcomes.
The study enrolled 516 premenopausal women with hormone receptor-positive, HER2-negative early breast cancer who wanted to attempt pregnancy. The results were indeed positive, with 76% of the 497 evaluable patients reporting at least one pregnancy, and 440 live births in total. This includes 18 sets of twins and 75 women with more than one live birth. Obstetric complication rates were consistent with population norms for women of a similar age, and no signal of harm was observed at 71 months.
One of the most compelling aspects of the study is the landmark analysis that addressed whether pregnancy itself poses a recurrence risk. Among participants with no evidence of disease at enrollment, those who became pregnant within 18 months had a breast cancer-free interval that was not statistically different from those who did not. In fact, the hazard ratio favored the pregnant group, suggesting that pregnancy may actually reduce the risk of recurrence.
Assisted reproductive technology (ART) was also found to be effective and apparently safe. Embryo transfer was associated with a more than doubling of the chance of pregnancy, and oncologic outcomes among ART users were comparable to those who did not require assisted reproduction. This reinforces the recommendation to discuss and facilitate fertility preservation at diagnosis for all premenopausal women with early-stage disease.
The POSITIVE trial has also provided valuable insights into endocrine therapy resumption and risk stratification. Adherence to endocrine therapy resumption after pregnancy was notably strong, with 72% of participants restarting treatment at 71 months. Recurrence predictors within the POSITIVE population tracked closely with established risk factors, such as nodal positivity, tumor size, and HER2 status.
The study also reviewed data from a matched analysis examining pregnancy outcomes in 4732 BRCA mutation carriers under the age of 40. One in five young carriers conceived within 10 years of breast cancer diagnosis, and their pregnancy was not associated with decreased disease-free survival. This suggests that pregnancy can be pursued safely by women with BRCA mutations as well.
In conclusion, the POSITIVE trial has provided a prospective, trial-level evidence base for counseling patients in a domain where only retrospective registry data had previously existed. It has offered a degree of reassurance that a time-limited, protocol-driven pause does not carry the oncologic penalties that had long been feared. However, Dr. Partridge cautioned that the results should not be read as a blanket endorsement of treatment interruption across all patients. Instead, they should be used to support patients as they make these difficult decisions.
Personally, I think the POSITIVE trial is a game-changer for women facing the dilemma of pregnancy after hormone receptor-positive breast cancer treatment. It has provided much-needed clarity and reassurance, and it has opened up new possibilities for women who want to pursue pregnancy after cancer. However, it is important to remember that every patient is unique, and the decision to pause treatment should be made on an individual basis, taking into account the patient's specific circumstances and preferences.
